Upgrade to SI Premium - Free Trial

Truist Securities Reiterates Buy Rating on Boston Scientific (BSX) amid buyback and third TAVR attempt

May 18, 2026 11:10 AM
Truist Securities analyst Richard Newitter reiterated a Buy rating and $85.00 price target on Boston Scientific (NYSE: BSX) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments